|Dr. James E. Brown D.V.M.||Co-Founder, CEO, Pres & Director||859.68k||N/A||1957|
|Ms. Judy R. Joice||Sr. VP of Operations & Corp. Quality Assurance||436.99k||102.25k||1957|
|Dr. Norman L. Sussman M.D.||Chief Medical Officer||570.32k||N/A||1953|
|Ms. Jian Li M.B.A.||Interim Principal Accounting Officer, Sr. VP of Fin., Corp. Controller & Sec.||N/A||N/A||1970|
|Dr. Andrew R. Miksztal Ph.D.||VP of Pharmaceutical R&D and Principal Scientist||N/A||N/A||N/A|
|Mr. Steve Helmer J.D.||VP & Chief Patent Counsel||N/A||N/A||N/A|
|Dr. WeiQi Lin||Exec. VP of R&D and Principal Scientist||N/A||N/A||N/A|
|Dr. Su Il Yum Ph.D.||Exec. Officer||N/A||N/A||1939|
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
DURECT Corporation’s ISS Governance QualityScore as of June 30, 2022 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 7.